Observation of Curative Efficacy and Prognosis Following Combination Chemotherapy with Celecoxib in the Treatment of Advanced Colorectal Cancer

被引：24

作者：

Jin, C-H ^{[1
]}

Wang, A-H ^{[1
]}

Chen, J-M ^{[1
]}

Li, R-X ^{[1
]}

Liu, X-M ^{[1
]}

Wang, G-P ^{[1
]}

Xing, L-Q ^{[1
]}

机构：

[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang 471003, Henan, Peoples R China

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2011年 / 39卷 / 06期

关键词：

CELECOXIB; CYCLOOXYGENASE-2; INHIBITORS; FOLFOX4; COLORECTAL CANCER; CYCLOOXYGENASE-2 (COX-2); EFFICACY; PROGNOSIS; INDUCED CYCLOOXYGENASE-2 EXPRESSION; CELL-CYCLE ARREST; COLON-CANCER; COX-2; INHIBITOR; CARCINOMA; APOPTOSIS; GROWTH; INDUCTION; PROTEINS;

D O I：

10.1177/147323001103900609

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer. A total of 90 patients were randomly divided into two groups: group CF was treated with a combination of celecoxib and the folinic acid-fluorouracil-oxaliplatin (FOLFOX4) regimen; and group F was treated with the FOLFOX4 regimen alone. Immunohistochemical analysis of tumour tissues for cyclooxygenase-2 (COX-2) protein was performed. With regard to short-term efficacy, the response and disease control rates were significantly greater in group CF than group F. A log-rank test showed that the 3-year survival rate was significantly greater in group CF than group F. It was concluded that the addition of celecoxib to the FOLFOX4 regimen increased the short-term efficacy and the 3-year survival rate, and improved the quality of life of patients with advanced colorectal cancer. The antitumour and chemosensitizing effects of celecoxib appeared to be independent of COX-2.

引用

页码：2129 / 2140

页数：12

共 49 条

[1]

Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer [J].

Altorki, NK ;

Port, JL ;

Zhang, F ;

Golijanin, D ;

Thaler, HT ;

Duffield-Lillico, AJ ;

Subbaramaiah, K ;

Dannenberg, AJ .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4191-4197

[2]

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial [J].

Bertagnolli, Monica M. ;

Eagle, Craig J. ;

Zauber, Ann G. ;

Redston, Mark ;

Breazna, Aurora ;

Kim, KyungMann ;

Tang, Jie ;

Rosenstein, Rebecca B. ;

Umar, Asad ;

Bagheri, Donya ;

Collins, Neal T. ;

Burn, John ;

Chung, Daniel C. ;

Dewar, Thomas ;

Foley, T. Raymond ;

Hoffman, Neville ;

Macrae, Finlay ;

Pruitt, Ronald E. ;

Saltzman, John R. ;

Salzberg, Bruce ;

Sylwestrowicz, Thomas ;

Hawk, Ernest T. .

CANCER PREVENTION RESEARCH, 2009, 2 (04) :310-321

[3]

Brabender J, 2002, ANN SURG, V235, P440, DOI 10.1097/00000658-200203000-00017

[4]

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer [J].

Cao, Y ;

Prescott, SM .

JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 190 (03) :279-286

[5]

Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2 [J].

Cheng, ASL ;

Chan, HLY ;

Leung, WK ;

To, KF ;

Go, MYY ;

Chan, JYH ;

Liew, CT ;

Sung, JJY .

MODERN PATHOLOGY, 2004, 17 (10) :1169-1179

[6]

Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? [J].

Choy, H ;

Milas, L .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1440-1452

[7]

Crespi Massimo, 2002, Med Arh, V56, P47

[8]

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[9]

The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells [J].

Elder, DJE ;

Halton, DE ;

Playle, LC ;

Paraskeva, C .

INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (03) :323-327

[10]

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? [J].

Gasparini, G ;

Longo, R ;

Sarmiento, R ;

Morabito, A .

LANCET ONCOLOGY, 2003, 4 (10) :605-615

← 1 2 3 4 5 →